The McCAVE Trial : Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
| dc.contributor.author | Bendell, Johanna C. | |
| dc.contributor.author | Sauri, Tamara | |
| dc.contributor.author | Gracian, Antonio Cubillo | |
| dc.contributor.author | Alvarez, Rafael | |
| dc.contributor.author | Lopez-Lopez, Carols | |
| dc.contributor.author | Garcia-Alfonso, Pilar | |
| dc.contributor.author | Hussein, Maen | |
| dc.contributor.author | Limon Miron, Maria-Luisa | |
| dc.contributor.author | Cervantes, Andres | |
| dc.contributor.author | Montagut, Clara | |
| dc.contributor.author | Santos Vivas, Cristina | |
| dc.contributor.author | Bessudo, Alberto | |
| dc.contributor.author | Plezia, Patrica | |
| dc.contributor.author | Moons, Veerle | |
| dc.contributor.author | Andel, Johannes | |
| dc.contributor.author | Bennouna, Jafaar | |
| dc.contributor.author | van der Westhuizen, Andre | |
| dc.contributor.author | Samuel, Leslie | |
| dc.contributor.author | Rossomanno, Simona | |
| dc.contributor.author | Boetsch, Christophe | |
| dc.contributor.author | Lahr, Angelika | |
| dc.contributor.author | Franjkovic, Izolda | |
| dc.contributor.author | Heil, Florian | |
| dc.contributor.author | Lechner, Katharina | |
| dc.contributor.author | Krieter, Oliver | |
| dc.contributor.author | Hurwitz, Herbert | |
| dc.contributor.institution | University of Aberdeen.Aberdeen Centre for Evaluation | en |
| dc.date.accessioned | 2020-03-17T10:25:01Z | |
| dc.date.available | 2020-03-17T10:25:01Z | |
| dc.date.issued | 2020-03 | |
| dc.description | We thank the patients and their families for their participation in this study and the staff at the study sites. This study and editorial support for the preparation of this manuscript were funded by F. Hoffmann-La Roche Ltd. Support for third-party writing assistance for this article, furnished by Goran Westerburg, Ph.D., was provided by La Crocina Pharmaceutical Consultants Lp. | en |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 9 | |
| dc.format.extent | 1033773 | |
| dc.identifier | 158966203 | |
| dc.identifier | 66c9e3dd-c631-48de-a3b0-234cb57deca2 | |
| dc.identifier | 85074443333 | |
| dc.identifier | 000488169200001 | |
| dc.identifier.citation | Bendell, J C, Sauri, T, Gracian, A C, Alvarez, R, Lopez-Lopez, C, Garcia-Alfonso, P, Hussein, M, Limon Miron, M-L, Cervantes, A, Montagut, C, Santos Vivas, C, Bessudo, A, Plezia, P, Moons, V, Andel, J, Bennouna, J, van der Westhuizen, A, Samuel, L, Rossomanno, S, Boetsch, C, Lahr, A, Franjkovic, I, Heil, F, Lechner, K, Krieter, O & Hurwitz, H 2020, 'The McCAVE Trial : Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)', Oncologist, vol. 25, no. 3, pp. e451-e459. https://doi.org/10.1634/theoncologist.2019-0291 | en |
| dc.identifier.doi | 10.1634/theoncologist.2019-0291 | |
| dc.identifier.iss | 3 | en |
| dc.identifier.issn | 1083-7159 | |
| dc.identifier.other | ORCID: /0000-0002-8402-8670/work/79064869 | |
| dc.identifier.uri | https://hdl.handle.net/2164/13875 | |
| dc.identifier.url | http://www.scopus.com/inward/record.url?scp=85074443333&partnerID=8YFLogxK | en |
| dc.identifier.vol | 25 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | Oncologist | en |
| dc.subject | SDG 3 - Good Health and Well-being | en |
| dc.subject | First-line metastatic colorectal cancer | en |
| dc.subject | Angiopoetin-2 | en |
| dc.subject | VEGF-A | en |
| dc.subject | Vanucizumab | en |
| dc.subject | Bevacizumab | en |
| dc.subject | BIOMARKER | en |
| dc.subject | ANTIBODY | en |
| dc.subject | PHASE-II | en |
| dc.subject | OXALIPLATIN | en |
| dc.subject | ANGIOPOIETIN-2 | en |
| dc.subject | ANTITUMOR-ACTIVITY | en |
| dc.subject | COMBINATION | en |
| dc.subject | HYPERTENSION | en |
| dc.subject | AMG 386 | en |
| dc.subject | CLINICAL-OUTCOMES | en |
| dc.subject | R Medicine | en |
| dc.subject | Oncology | en |
| dc.subject | Cancer Research | en |
| dc.subject | Supplementary Data | en |
| dc.subject.lcc | R | en |
| dc.title | The McCAVE Trial : Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC) | en |
| dc.type | Journal article | en |
Files
Original bundle
1 - 1 of 1
- Name:
- bendell_et_al_TO_the_McCAVE_trial_VoR.pdf
- Size:
- 1009.54 KB
- Format:
- Adobe Portable Document Format
